Carregant...
Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma
Pembrolizumab is a long-awaited drug for the treatment of metastatic urothelial carcinoma. It is an immune checkpoint inhibitor, which has been shown to trigger new autoimmune disorders. We report a case of pembrolizumab-induced myasthenia gravis that occurred in an 84-year-old Japanese female with...
Guardat en:
| Publicat a: | Int Cancer Conf J |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Singapore
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7297883/ https://ncbi.nlm.nih.gov/pubmed/32582515 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13691-020-00408-4 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|